UCB and Biogen's Drug Trial Achieves Success
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 43 minutes ago
0mins
Source: seekingalpha
- Clinical Trial Results: UCB and Biogen's dapirolizumab pegol met its primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a BICLA response at week 48 compared to 35% on placebo (p=0.011), indicating significant clinical benefit of the drug.
- Treatment Effectiveness Assessment: BICLA serves as a composite endpoint measuring clinically relevant improvement across all affected organ systems without worsening in other lupus domains, reflecting the efficacy of dapirolizumab pegol in treatment, despite the first key secondary endpoint not being met.
- Adverse Event Rates: The serious adverse event rate for dapirolizumab pegol was 10%, lower than the 14.8% observed in the placebo group, suggesting a relatively higher safety profile for the drug, which may enhance patient confidence in treatment.
- Future Research Plans: The confirmatory phase 3 PHOENYCS FLY trial is currently recruiting patients, aiming to further validate the efficacy and safety of dapirolizumab pegol, laying the groundwork for future market introduction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 196.390
Low
143.00
Averages
204.45
High
246.00
Current: 196.390
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dapirolizumab Pegol Shows Significant Clinical Trial Results
- Clinical Trial Results: In the PHOENYCS GO study, 50% of patients receiving Dapirolizumab Pegol plus standard of care achieved a BICLA response at Week 48, significantly higher than the 35% in the placebo group, indicating its potential in treating systemic lupus erythematosus (SLE).
- Improvement Across Multiple Metrics: The study demonstrated that Dapirolizumab Pegol showed advantages across various disease activity measures, including severe BILAG flares, SLEDAI-2K scores, and patient-reported fatigue, highlighting its positive impact on patients' quality of life.
- Glucocorticoid Sparing Effect: At Week 48, a greater proportion of patients in the Dapirolizumab Pegol group successfully reduced their glucocorticoid dose from >7.5 mg/day to ≤7.5 mg/day, suggesting a glucocorticoid-sparing effect that aligns with treatment guidelines.
- Favorable Safety Profile: The safety profile of Dapirolizumab Pegol was consistent with previous studies, with treatment-emergent adverse events occurring in 82.6% of patients, but serious adverse events were lower at 10.0%, indicating its feasibility for clinical use.
See More
UCB and Biogen's Drug Trial Achieves Success
- Clinical Trial Results: UCB and Biogen's dapirolizumab pegol met its primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a BICLA response at week 48 compared to 35% on placebo (p=0.011), indicating significant clinical benefit of the drug.
- Treatment Effectiveness Assessment: BICLA serves as a composite endpoint measuring clinically relevant improvement across all affected organ systems without worsening in other lupus domains, reflecting the efficacy of dapirolizumab pegol in treatment, despite the first key secondary endpoint not being met.
- Adverse Event Rates: The serious adverse event rate for dapirolizumab pegol was 10%, lower than the 14.8% observed in the placebo group, suggesting a relatively higher safety profile for the drug, which may enhance patient confidence in treatment.
- Future Research Plans: The confirmatory phase 3 PHOENYCS FLY trial is currently recruiting patients, aiming to further validate the efficacy and safety of dapirolizumab pegol, laying the groundwork for future market introduction.
See More
Italy Investigates Biogen for Market Dominance Abuse
- Market Dominance Investigation: The Italian Competition Authority has launched an investigation into Biogen (BIIB) for allegedly abusing its dominant position to hinder Sandoz (SDZXF) from selling a competing multiple sclerosis medication, raising concerns about unfair market practices.
- Antitrust Action Details: Officials from Italy's antitrust authority and the Special Antitrust Unit of the Italian Financial Police conducted inspections at Biogen's Italian premises on Tuesday, reflecting the regulator's serious commitment to ensuring competition in the pharmaceutical market.
- Market Impact: Following Biogen's loss of exclusivity for Tysabri (natalizumab) in 2024, Sandoz introduced a low-cost biosimilar, with the regulator noting that Biogen's actions may have prevented Italy's National Health Service from realizing at least 20% in cost savings associated with biosimilars.
- Cooperation Statement: Biogen stated it is
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
Biogen Shares Plunge 6.4% After CELIA Trial Misses Endpoint
- Trial Failure: On May 14, 2026, Biogen disclosed that its CELIA trial for diranersen failed to meet its primary dose-response endpoint, resulting in a 6.4% drop in stock price and billions in market value loss, indicating a market reassessment of the company's near-term pipeline value.
- Investor Losses: Many investors, particularly those who purchased Biogen shares at higher prices, are facing significant losses and may be eligible to participate in legal investigations aimed at recovering damages related to the trial's disappointing results.
- Market Reaction: Following the release of the CELIA trial data, Biogen's stock experienced a sharp decline on heavy trading volume, reflecting investor concerns about the company's future prospects, especially given management's previous confidence expressed during the Q1 2025 earnings call.
- Legal Investigation Initiated: The law firm Levi & Korsinsky has launched an investigation into whether Biogen made materially false or misleading statements regarding its pipeline prospects and the status of the CELIA trial, encouraging investors to gather trading records to participate in potential legal actions.
See More
Biogen and Denali Halt Development of Parkinson's Drug BIIB122
- Trial Setback: Biogen (BIIB) and Denali (DNLI) announced the discontinuation of BIIB122 after their Phase 2b LUMA study for early-stage Parkinson's disease failed to meet primary and secondary endpoints, marking a significant setback in their drug development efforts.
- Mechanism Exploration: BIIB122 was designed to inhibit the LRRK2 mutation associated with Parkinson's disease; despite the disappointing results, Denali's medical chief, Peter Chin, emphasized the need for further exploration of LRRK2 as a potential therapeutic target, indicating future research directions.
- Continued Research: Denali will proceed with its Phase 2a BEACON study for BIIB122 in LRRK2-associated Parkinson's disease, which is expected to generate data in H1 2027, potentially providing new insights into treatment options in this area.
- Market Reaction: Following the announcement, shares of Biogen and Denali fell in premarket trading on Friday, reflecting investor concerns about the companies' prospects in the neurodegenerative disease space, which may impact future funding and R&D investments.
See More
Dapirolizumab Pegol Shows Significant Clinical Trial Results
- Clinical Trial Results: In the PHOENYCS GO study, 50% of patients receiving Dapirolizumab Pegol plus standard of care achieved a BICLA response at Week 48, significantly higher than the 35% in the placebo group, indicating its potential in treating systemic lupus erythematosus (SLE).
- Improvement Across Multiple Metrics: The study demonstrated that Dapirolizumab Pegol showed advantages across various disease activity measures, including severe BILAG flares, SLEDAI-2K scores, and patient-reported fatigue, highlighting its positive impact on patients' quality of life.
- Glucocorticoid Sparing Effect: At Week 48, a greater proportion of patients in the Dapirolizumab Pegol group successfully reduced their glucocorticoid dose from >7.5 mg/day to ≤7.5 mg/day, suggesting a glucocorticoid-sparing effect that aligns with treatment guidelines.
- Favorable Safety Profile: The safety profile of Dapirolizumab Pegol was consistent with previous studies, with treatment-emergent adverse events occurring in 82.6% of patients, but serious adverse events were lower at 10.0%, indicating its feasibility for clinical use.
See More
UCB and Biogen's Drug Trial Achieves Success
- Clinical Trial Results: UCB and Biogen's dapirolizumab pegol met its primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a BICLA response at week 48 compared to 35% on placebo (p=0.011), indicating significant clinical benefit of the drug.
- Treatment Effectiveness Assessment: BICLA serves as a composite endpoint measuring clinically relevant improvement across all affected organ systems without worsening in other lupus domains, reflecting the efficacy of dapirolizumab pegol in treatment, despite the first key secondary endpoint not being met.
- Adverse Event Rates: The serious adverse event rate for dapirolizumab pegol was 10%, lower than the 14.8% observed in the placebo group, suggesting a relatively higher safety profile for the drug, which may enhance patient confidence in treatment.
- Future Research Plans: The confirmatory phase 3 PHOENYCS FLY trial is currently recruiting patients, aiming to further validate the efficacy and safety of dapirolizumab pegol, laying the groundwork for future market introduction.
See More
Italy Investigates Biogen for Market Dominance Abuse
- Market Dominance Investigation: The Italian Competition Authority has launched an investigation into Biogen (BIIB) for allegedly abusing its dominant position to hinder Sandoz (SDZXF) from selling a competing multiple sclerosis medication, raising concerns about unfair market practices.
- Antitrust Action Details: Officials from Italy's antitrust authority and the Special Antitrust Unit of the Italian Financial Police conducted inspections at Biogen's Italian premises on Tuesday, reflecting the regulator's serious commitment to ensuring competition in the pharmaceutical market.
- Market Impact: Following Biogen's loss of exclusivity for Tysabri (natalizumab) in 2024, Sandoz introduced a low-cost biosimilar, with the regulator noting that Biogen's actions may have prevented Italy's National Health Service from realizing at least 20% in cost savings associated with biosimilars.
- Cooperation Statement: Biogen stated it is
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
Biogen Shares Plunge 6.4% After CELIA Trial Misses Endpoint
- Trial Failure: On May 14, 2026, Biogen disclosed that its CELIA trial for diranersen failed to meet its primary dose-response endpoint, resulting in a 6.4% drop in stock price and billions in market value loss, indicating a market reassessment of the company's near-term pipeline value.
- Investor Losses: Many investors, particularly those who purchased Biogen shares at higher prices, are facing significant losses and may be eligible to participate in legal investigations aimed at recovering damages related to the trial's disappointing results.
- Market Reaction: Following the release of the CELIA trial data, Biogen's stock experienced a sharp decline on heavy trading volume, reflecting investor concerns about the company's future prospects, especially given management's previous confidence expressed during the Q1 2025 earnings call.
- Legal Investigation Initiated: The law firm Levi & Korsinsky has launched an investigation into whether Biogen made materially false or misleading statements regarding its pipeline prospects and the status of the CELIA trial, encouraging investors to gather trading records to participate in potential legal actions.
See More
Biogen and Denali Halt Development of Parkinson's Drug BIIB122
- Trial Setback: Biogen (BIIB) and Denali (DNLI) announced the discontinuation of BIIB122 after their Phase 2b LUMA study for early-stage Parkinson's disease failed to meet primary and secondary endpoints, marking a significant setback in their drug development efforts.
- Mechanism Exploration: BIIB122 was designed to inhibit the LRRK2 mutation associated with Parkinson's disease; despite the disappointing results, Denali's medical chief, Peter Chin, emphasized the need for further exploration of LRRK2 as a potential therapeutic target, indicating future research directions.
- Continued Research: Denali will proceed with its Phase 2a BEACON study for BIIB122 in LRRK2-associated Parkinson's disease, which is expected to generate data in H1 2027, potentially providing new insights into treatment options in this area.
- Market Reaction: Following the announcement, shares of Biogen and Denali fell in premarket trading on Friday, reflecting investor concerns about the companies' prospects in the neurodegenerative disease space, which may impact future funding and R&D investments.
See More
